Boston Scientific reported lower third-quarter profit on October 28 and projected a year-over-year sales decline for the final quarter of 2026, according to its earnings release.
Sales reached $5.138 billion in the quarter ended September 30, increasing 1.5% from a year earlier. Net income attributable to common stockholders fell to $582 million from $755 million. Diluted earnings declined to 40 cents per share from 51 cents.
Adjusted earnings were 73 cents per share, compared with 75 cents a year earlier. The adjusted measure excludes specified charges and credits and supplements standard accounting results.
Sales increased 0.6% in the MedSurg segment and 1.9% in Cardiovascular. U.S. sales grew 0.5%, while Asia-Pacific sales declined 0.6% on a reported basis.
The company now forecasts full-year reported sales growth of approximately 4.25% and adjusted earnings of $3.16 to $3.18 per share. For the fourth quarter, it expects sales to fall 1% to 3% and adjusted earnings of 77 to 79 cents per share.
Those figures are management forecasts, distinct from the completed quarterly results.
Sources: Boston Scientific earnings release, October 28, 2026.